在出院外科手术患者的CYP2D6代谢中CYP2D6活性的人口药理动力量化,以模型为基础的精确剂量
Muhammad Waqar Ashraf1, Satu Poikola2, Mikko Neuvonen3,4
1Department of Anaesthesiology and Intensive Care, University of Turku, Kiinamyllynkatu 4-8, P.O. Box 52, 20520, Turku, Finland.
Clinical pharmacokinetics
|October 23, 2024
概括
在CYP2D6的遗传变异显著影响代因代谢. 这项研究量化了CYP2D6基因型如何影响吗啡暴露,为个性化编码因疗法提供信息并减少不良事件.
科学领域:
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
- 临床药理学 临床药理学
背景情况:
- 代代因代谢涉及多个细胞染色体P450 (CYP) 酶,对酶表达有显著的遗传影响.
- 多态CYP2D6将编码因代谢为吗啡,其活性与编码因的不良影响有很强的相关性.
研究的目的:
- 量化CYP2D6基因型对可代因生物转化的影响.
- 根据遗传变异开发一个模型来预测基于基因变异的可代因和吗啡暴露.
主要方法:
- 潜在的临床试验涉及1000名接受编码因的患者.
- 种群药动力学建模以量化CYP2D6活性和跨基因型的吗啡暴露.
- 作为共变量使用的CYP2D6基因型和活性评分.
主要成果:
- 该模型准确地预测了可代因排放和代谢物形成,考虑到CYP2D6基因型.
- 超急性CYP2D6代谢剂显著增加了吗啡的暴露,可能导致呼吸抑制.
- 与正常代谢者相比,较差和中间代谢者显著减少了吗啡暴露.
结论:
- 开发的模型支持可代因治疗的模型知情精确剂量.
- 对CYP2D6基因型的基因检测对于用可代因进行合理的药物治疗至关重要.
更多相关视频
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
90
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
90
Analysis of Population Pharmacokinetic Data
235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
49
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
49
Pharmacokinetic Models: Comparison and Selection Criterion
46
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
46
One-Compartment Open Model for IV Bolus Administration: General Considerations
165
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
165
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
32
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
32


